Nexstim Plc · OMXHEX:NXTMH
Nexstim — BioStock Life Science Summit 2025
7 slides from Nexstim's conference presentation, Nov 12, 2025
Slide 1: BioStock, Life Science Summit
BioStock, Life Science Summit Lund, 12 November 2025 Mikko Karvinen, CEO Nexstim Plc
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj obligation to update or revise this document. (“Nexstim” or the “Company”). In connection with any presentation or review of this document, you agree to be bound by the following limitations a
Slide 3: Nexstim nTMS solutions and business areas
Nexstim nTMS solutions and business areas LTM H1 ‘25 sales Business area System Application Devices sold(2) growth 256 Pre-surgical Diagnostics NBS 5, NBS 6 mapping +27% CE marked FDA approved 121(3) Depression and Therapy NBT®, NBS 6 chronic pain +12% CE marked FDA approved(1) Not disclosed(4) Rese
Slide 4: Financials – Ramping up for profitable growth
Financials – Ramping up for profitable growth Strong growth with scaling fixed cost base Key operational milestones Net sales (EURm) Gross margin % EBITDA (EURm) +1,112% 1,0 ▶ Strong revenue momentum, with net 0,3 0,1 sales up +39% CAGR since LTM H1 ‘23, 79% 79% 80% 79% 80% driven by therapy and rec
Slide 5: Q3 update – delivering growth and global impact
Q3 update – delivering growth and global impact +45% deliveries growth YoY Strengthening market presence Key highlights Therapy Diagnostics ▶ Summary of key events attended during ▶ Strong diagnostics momentum: 13 H2 ‘25 to date systems delivered (+160% YoY) and 7 Excluding Research & – Brain Comput
Slide 6: Strong momentum with several growth catalysts
Strong momentum with several growth catalysts +73% 4,1 2,4 NBS 6 H2 ’20 H1 ’25 Recurring revenue LTM (EURm) Leveraging FDA and CE Increasing system sales Launching the new NBS 6 Major market opportunity Increasing installed base approvals to grow volume through Brainlab diagnostics system and for tr
Slide 7: Key investment highlights
Key investment highlights 1 Broad and attractive market with multiple clinical use cases 2 Leading proprietary technology with key regulatory approvals 3 Strong competitive entry barriers in a highly regulated market 4 Stellar financial profile – double digit growth, steady and high gross margins, s